EISAI R & D MANAGEMENT CO. LTD.;MERCK SHARP AND DOHME CORP.
发明人:
申请号：
IL25413317
公开号：
IL254133D0
申请日:
2017.08.24
申请国别(地区):
IL
年份:
2017
代理人:
摘要：
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
